SOURCE: Ablynx

June 22, 2010 12:17 ET

ABLYNX EXPANDS INTO NEW R&D FACILITIES

GHENT, BELGIUM--(Marketwire - June 22, 2010) -


GHENT, Belgium, 22 June 2010 - Ablynx [Euronext Brussels: ABLX] announced today that it has moved into new R&D facilities located on the Technologiepark in Zwijnaarde, near Ghent.

Ablynx will lease 8,000 m(2) of the brand new 10,000 m(2) building which is located on the same Technologiepark as Ablynx's previous facilities.

"This new cutting-edge laboratory building will support Ablynx's growth in the foreseeable future. This allows us to house our Belgian operations in one facility", said Dr Edwin Moses, Chief Executive Officer and Chairman of Ablynx. "With over 240 staff we believe Ablynx is one of the most advanced independent, next-generation biologics companies."

-ends-

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 240 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised EUR50 million through an SPO in March 2010.

Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 190 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to address with conventional monoclonal antibodies. Efficacy data have been obtained in 28 in vivo models for Nanobodies against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.

For more information, please contact Ablynx:

Dr. Edwin Moses
Chairman and CEO
t:  +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:  +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com

[HUG#1426291]

Complete version of the press release: http://hugin.info/137912/R/1426291/374238.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

All reproduction for further distribution is prohibited.

Source: Ablynx via Thomson Reuters ONE

Contact Information